Gln²⁷→Gluβ₂‐Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol

Abstract

Abstract: We investigated the clinical response of chronic heart failure patients with β 2 ‐adrenergic receptor Gln 27 →Glu polymorphism treated for 6 months with carvedilol, a α/β‐antagonist with antioxidant properties. The 6‐min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln 27 →Gluβ 2 ‐adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27 β 2 ‐adrenergic receptor allele. There were however, no significant changes in patients with the Gln 27 β 2 ‐adrenergic receptor variant.